Names and pronunciation
(mi-kon′a-zole) Oravig (OTC) Baza, Desenex, Fungoid, Lotrimin AF, Micaderm, Micatin, Micozole , Monistat-1, Monistat-3, Monistat-7, M-Zole 3, Vagistat-3, Zeasorb-AF
Source page 886
Loading InternPractice…
Individual generic drug information
Extracted information for miconazole only.
(mi-kon′a-zole) Oravig (OTC) Baza, Desenex, Fungoid, Lotrimin AF, Micaderm, Micatin, Micozole , Monistat-1, Monistat-3, Monistat-7, M-Zole 3, Vagistat-3, Zeasorb-AF
Source page 886
Func. class.: Antifungal
Source page 886
Chem. class.: Imidazole
Source page 886
Do not confuse: miconazole/clotrimazole/ metroNIDAZOLE
Source page 886
ACTION: Antifungal activity results from disruption of cell membrane permeability
Source page 887
USES: Treatment of topical fungal infection, vulvovaginal candidiasis; ath- lete’s foot (tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis)
Source page 887
Extracted information for miconazole only.
CONTRAINDICATIONS: Hyper- sensitivity to this product or imidazoles; pregnancy first trimester (vaginal) Precautions: Breastfeeding, children
Source page 887
SIDE EFFECTS CNS: Headache GI: Diarrhea, nausea GU: Pruritus, irritation, vaginal burning INTEG: Burning, dermatitis, rash DRUG INTERACTIONS Increase: anticoagulant effect—(buc- cal) monitor PT, INR Decrease: effect (vaginal)—progesterone Drug/Lab Decrease: WBC, RBC (buccal)
Source page 887
Extracted information for miconazole only.
DOSAGE AND ROUTES Oropharyngeal candidiasis (thrush) • Adult/adolescent ≥16 yr: BUCCAL ap- ply 1 tab (50 mg) to upper gum region, just above incisor daily × 14 days Tinea corporis, cruris, pedis; cutaneous candidiasis • Adult/child >2 yr: TOP apply bid × 2-4 wk Tinea versicolor • Adult/child >2 yr: TOP use bid × 2 wk, apply sparingly every day Vulvovaginal candidiasis • Adult/child ≥12 yr: VAG 1 applicator- ful of Monistat-7 (100 mg) or 1 supp (100 mg) at bedtime × 7 days, repeat if needed, or Monistat-3 (200 mg) × 3 days or a 1200 mg supp × 1 day
Source page 887
Available forms: Topical cream, ointment, solution, lotion, powder, aerosol, powder 2%; aerosol spray 2%; vag cream 2, 4%; vag supp 100, 200, 1200 mg; buccal tab 50 mg
Source page 887
Administer: Transmucosal use (adhesive buccal tablet) • Place the rounded surface of the tab against the upper gum just above the in- cisor tooth, hold in place with slight pressure over the upper lip for 30 sec to assure adhesion • The tab will gradually dissolve • Administration of subsequent tab should be made to alternate sides of the mouth • Before applying the next tab, clear away any remaining tab material • Do not crush, chew, or swallow; food and drink can be taken normally; avoid chewing gum • If tab does not adhere or falls off within the first 6 hr, the same tab should be repo- sitioned; if the tab still does not adhere, a new tab should be used • If the tab falls off or is swallowed after it was in place for 6 hr or more, a new tab should not be applied until the next regularly scheduled dose Topical route • Topical skin products are not for intra- vaginal therapy and are for external use only; do not use skin products near the eyes, nose, or mouth • Wash hands before and after use; wash affected area and gently pat dry • Cream/ointment/lotion/solution: apply a thin film to the cleansed affected area; massage gently into affected areas • Solution formulations: apply a thin film to the cleansed affected area; mas- sage gently into affected areas; if using a solution-soaked pledget, patient may use M more than 1 pledget per application as needed • Intravaginal route: only use dosage formulations specified for intravaginal use • Suppository: unwrap, use applicator(s) supplied by the manufacturer • Cream: use applicator(s) supplied by the manufacturer
Source page 887
Extracted information for miconazole only.
Assess: • Allergic reaction: assess for hypersen- sitivity; product may need to be discon- tinued • Infection: assess for severity of infec- tion • Pregnancy/breastfeeding: use cau- tiously in breastfeeding; use PO form in pregnancy only if benefits outweigh risk to fetus, no adequate studies
Source pages 887, 888
Evaluate: • Decreasing severity of infection
Source page 888
CLINICAL CONSIDERATIONS
Source page 887
Patient and caregiver information: Topical route • That topical skin products are not for intravaginal therapy and are for external use only; not to use skin products near the eyes, nose, or mouth • To wash hands before and after use; wash affected area and gently pat dry • Cream/ointment/lotion/solution: to ap- ply a thin film to the cleansed affected area and massage gently into affected areas • Solution formulations: to shake well before use, apply a thin film to the cleansed affected area, and massage gen- tly into affected areas Intravaginal route • To only use dosage formulations speci- fied for intravaginal use; not to ingest in- travaginal dosage forms; not to use tam- pons, douches, spermicides; not to engage in sexual activity; product may damage condoms, diaphragms, cervical caps • Suppository: to unwrap vaginal ovule (suppository) before inserting; to use applicator(s) supplied by the manufacturer • Cream: to use applicator(s) supplied by the manufacturer HIGH ALERT
Source page 888
Filter the extracted dose blocks for this individual drug.
Oropharyngeal candidiasis (thrush)
• Adult/adolescent ≥16 yr: BUCCAL ap- ply 1 tab (50 mg) to upper gum region, just above incisor daily × 14 days Tinea corporis, cruris, pedis; cutaneous candidiasis
Candidate age grouping · source page 887
Oropharyngeal candidiasis (thrush)
• Adult/child >2 yr: TOP apply bid × 2-4 wk Tinea versicolor
Candidate age grouping · source page 887
Oropharyngeal candidiasis (thrush)
• Adult/child >2 yr: TOP use bid × 2 wk, apply sparingly every day Vulvovaginal candidiasis
Candidate age grouping · source page 887
Oropharyngeal candidiasis (thrush)
• Adult/child ≥12 yr: VAG 1 applicator- ful of Monistat-7 (100 mg) or 1 supp (100 mg) at bedtime × 7 days, repeat if needed, or Monistat-3 (200 mg) × 3 days or a 1200 mg supp × 1 day
Candidate age grouping · source page 887